Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.40−0.08 (-0.52%)
Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –
Aurinia Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aurinia Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $177.16M, up 47.5% year over year. For fiscal 2025 it was $135.66M, up 205.6% from the year before. The highest annual figure on record is $135.66M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $135.66M | +205.6% |
| FY2024 | Dec 31, 2024 | $44.39M | – |
| FY2023 | Dec 31, 2023 | -$33.46M | – |
| FY2022 | Dec 31, 2022 | -$79.53M | – |
| FY2021 | Dec 31, 2021 | -$157.69M | – |
| FY2020 | Dec 31, 2020 | -$69.86M | – |
| FY2019 | Dec 31, 2019 | -$63.59M | – |
| FY2018 | Dec 31, 2018 | -$51.61M | – |
| FY2017 | Dec 31, 2017 | -$41.17M | – |
| FY2016 | Dec 31, 2016 | -$18.71M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $46.37M | +4.3% |
| Q2 FY2026 | Jun 30, 2026 | $52.57M | +18.8% |
| Q1 FY2026 | Mar 31, 2026 | $32.56M | +2404.6% |
| Q4 FY2025 | Dec 31, 2025 | $45.67M | +51.7% |
| Q3 FY2025 | Sep 30, 2025 | $44.45M | +161.0% |
| Q2 FY2025 | Jun 30, 2025 | $44.24M | +179.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.30M | – |
| Q4 FY2024 | Dec 31, 2024 | $30.11M | +110.4% |
| Q3 FY2024 | Sep 30, 2024 | $17.03M | – |
| Q2 FY2024 | Jun 30, 2024 | $15.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.60M | – |
| Q4 FY2023 | Dec 31, 2023 | $14.31M | +37.0% |
| Q3 FY2023 | Sep 30, 2023 | -$13.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.67M | – |
| Q4 FY2022 | Dec 31, 2022 | $10.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$46.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.92M | -909.1% |
| Q3 FY2021 | Sep 30, 2021 | -$40.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.98M | – |
| Q1 FY2021 | Mar 31, 2021 | -$53.54M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.61M | – |
See a number that looks wrong?